Clobazam and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Clobazam (clobazam), especially for people who are male, 50-59 old, also take Keppra, and have Glioblastoma.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Clobazam. It is created by eHealthMe based on reports of 14,346 people who have side effects when taking Clobazam from the FDA, and is updated regularly.

What is Clobazam?

Clobazam has active ingredients of clobazam. eHealthMe is studying from 14,399 Clobazam users. Check the latest studies of Clobazam.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,080 drugs and 906 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

On Apr, 17, 2026

14,346 people reported to have side effects when taking Clobazam.
Among them, 14 people (0.1%) have Neoplasm progression.

Could Clobazam cause Neoplasm progression?

Among these 14 people:

What is the gender of people who have Neoplasm progression when taking Clobazam? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Neoplasm progression when taking Clobazam? *

What are other drugs people take besides Clobazam? *

What are other side effects people have besides Neoplasm progression? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 35.71%
Headache (pain in head): 4 people, 28.57%
Nasopharyngitis (inflammation of the nasopharynx): 4 people, 28.57%
Nausea (feeling of having an urge to vomit): 4 people, 28.57%
Drug Ineffective: 3 people, 21.43%
Mobility Decreased (ability to move is reduced): 3 people, 21.43%
Fatigue (feeling of tiredness): 3 people, 21.43%
Diarrhea: 3 people, 21.43%
Weight Increased: 3 people, 21.43%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 3 people, 21.43%

What are the existing conditions these people have? *

Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 8 people, 57.14%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 14.29%
Gastritis (inflammation of stomach): 1 person, 7.14%
Appetite Disorder (abnormal eating habits): 1 person, 7.14%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 7.14%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 7.14%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 1 person, 7.14%
Depression: 1 person, 7.14%
Dyslipidaemia (abnormal amount of lipids): 1 person, 7.14%
Stress And Anxiety: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Clobazam and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Clobazam:

Clobazam (14,399 reports)

Browse all side effects of Clobazam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,080 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (906 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on clobazam (the active ingredients of Clobazam) and Clobazam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.